Janssen Pharmaceutica NV has synthesized endosomal/lysosomal proton channel TMEM175 activators reported to be useful for the treatment of Parkinson’s disease.
Matricelf Ltd. has initiated a pivotal IND-enabling efficacy study evaluating its engineered human neural tissue implant for the treatment of chronic spinal cord injury.
Researchers from Bayer AG reported the discovery and preclinical characterization of BAY-439, a potent and selective hPLA2-G5 inhibitor, in models of pain.
Anhorn Medicines Co. Ltd. has obtained IND clearance from the FDA for its lead neuroprotective candidate, AH-008, for the prevention of chemotherapy-induced peripheral neuropathy.
Lys Therapeutics SAS is advancing LYS-241 toward the clinic with the support of more than €25 million (US$33 million) in funding raised since the company’s inception in 2021. The financing includes a grant of more than $5 million from The Michael J. Fox Foundation.
Evotec International GmbH has reported new prodrugs of NLRP3 inflammasome inhibitors potentially useful for the treatment of inflammation, asthma, hypertension, myocardial infarction, neurological disorders, silicosis, graft-vs.-host and metabolic diseases.
Zhejiang Jingke Pharmaceuticals Co. Ltd. has disclosed new deuterated isoindoline compounds acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands. They are described as potentially useful for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, dry macular degeneration, rheumatoid arthritis, asthma, Alzheimer's and Parkinson's disease.
Bioarctic AB has entered into a research and collaboration agreement with Eli Lilly and Co. on a new treatment in the field of neurodegeneration. The collaboration will see Bioarctic generate a new drug candidate combining its Braintransporter technology with an undisclosed Lilly molecule.
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as AP2-associated protein kinase 1 (AAK1) inhibitors that are potentially useful for the treatment of Alzheimer’s disease, bipolar disorder, Parkinson’s disease, diabetic peripheral neuropathy, postherpetic neuralgia (PHN) and schizophrenia.
Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.
RSS
